Startup Deep Dive : Tata 1mg — revenue near Rs 2,936 crore, but investors want it valued 40% below its 2022 peak

Tata 1mg closed FY26 with revenue near ₹2,936 crore ($306 million), up 23% for the year, and one of its two operating units actually turned a profit. Yet through the second half of 2025, global investors sitting across the table from Tata Sons were pushing to value the company at $750-800 million — nearly 40% below the $1.25 billion mark it carried when it became a unicorn in 2022.

That contradiction, growing revenue and a shrinking price tag, is the story of Tata 1mg. It is a company that has been rescued once already, that still loses money on the visible half of its business while quietly making money on the half nobody talks about, and that is now finding out that scale in Indian e-pharmacy does not automatically translate into the valuation its earlier backers were promised.

Quick facts

What they do

Tata 1mg sells medicines, runs diagnostic tests and offers doctor consultations through an app and website that reach more than 20,000 pin codes for delivery, backed by a growing chain of retail pharmacy stores and a network of NABL-accredited labs. Its customers range from a patient in a small town ordering a month’s diabetes medication online to a corporate health plan buying an annual check-up package, and its buyers on the other side include pharmaceutical companies that pay for patient-support programmes and advertising placement inside the app. In effect, it is trying to be the neighbourhood chemist, the diagnostic lab and the family doctor’s reception desk, rolled into one app, for a country where all three have historically been fragmented, unbranded and unevenly regulated.

The origin

The company’s origin lies inside another startup. Prashant Tandon and Vikas Chauhan had already founded Healthkart, a nutrition and wellness e-commerce site, in 2011; Gaurav Agarwal, an IIT-Delhi graduate who had worked at Zynga’s FarmVille and at NetApp, joined in 2013. Inside Healthkart, the team built HealthkartPlus, a simple tool that let users search for medicines and compare prices, mainly as an information layer rather than a transaction one. Tandon, an IIT-Delhi and Stanford graduate who had passed through McKinsey, Hindustan Lever and MapMyIndia, has described the founding insight in interviews as the discovery that Indian patients did not lack access to information about medicines so much as a trustworthy, single place to find it and then act on it. The demand came from users themselves, who kept asking HealthkartPlus to also deliver the medicines it was helping them find. That user pull, not a founder’s original plan, is what pushed the company to spin the vertical out and relaunch it in April 2015 under a new name built around dosage: 1mg.

The struggle years

1mg’s hardest years were not really about running out of money once; they were about two different kinds of near-misses, one regulatory and one financial. The regulatory one came first. India has never had a dedicated law for e-pharmacies, and the entire sector has operated for years on interpretations of the Drugs and Cosmetics Act and pharmacy-practice rules written for physical chemist shops. That ambiguity turned into an existential threat when the Delhi High Court, acting on a public interest petition, ordered a nationwide ban on the online sale of medicines. 1mg, along with rivals such as Netmeds and PharmEasy, had to rebuild its ordering flow around mandatory prescription uploads and pharmacist verification simply to keep operating, according to an account of the episode published by StartupTalky. The ban was not a one-line inconvenience: it forced every e-pharmacy in the country, 1mg included, to prove it could function as a compliant pharmacy rather than a discount marketplace, or risk being shut out of medicine delivery altogether.

The second near-miss was financial, and it came after the company was already part of the Tata group. In FY23, two years into Tata Digital’s ownership, 1mg posted a consolidated net loss of ₹1,255 crore against revenue of ₹1,627 crore, according to regulatory filings reported by Inc42 and Entrackr — its widest loss on record, driven by heavy spending that included ₹135 crore in advertising alone that year. That is a loss roughly three-quarters the size of that year’s entire revenue, the kind of ratio that forces a rethink of the underlying model rather than a tweak to it. The company’s response was blunt: advertising spend was cut 37% the following year and employee costs were trimmed 5%, and the loss fell 75% to ₹313 crore in FY24 even as revenue kept growing. The FY23 loss functioned as the company’s real balance-sheet scare, arriving not before the safety net of Tata ownership but inside it, which is what forced the shift from growth-at-any-cost to a visible focus on unit economics.

The turning point

The clearest single hinge in the company’s history is the sale itself. Before Tata Digital came in, 1mg had raised a cumulative $156 million and was valued at roughly $242 million, according to Tracxn data cited by TechCrunch — respectable for an Indian health-tech startup of that era, but well short of the war chest that rival PharmEasy was raising at the time. In June 2021, Tata Digital agreed to invest $220 million in primary and secondary capital for a majority stake reported at around 55%, valuing the company at roughly $400-450 million, per TechCrunch’s reporting at the time (Inc42 later cited a lower estimated investment figure of $100-120 million in a 2024 retrospective, a reminder that deal-size reporting on Indian private rounds is rarely precise). Whatever the exact cheque size, the effect was immediate: a company that had been raising $15-50 million at a time was suddenly backed by one of India’s largest conglomerates, alongside its BigBasket and Croma bets under the same Tata Digital umbrella. Within about 18 months, riding that balance sheet, 1mg closed a further round that pushed its valuation to $1.25 billion and made it a unicorn — a leap in perceived value that had far less to do with its own operating metrics changing overnight than with the credibility of its new parent.

The money behind it

Before Tata, 1mg’s capital came almost entirely from venture investors: Sequoia Capital India and Omidyar Network backed it from an early $6 million round in 2015 through a $15 million Series B alongside Maverick Ventures in 2016; HBM Healthcare Investments led a $15 million round in 2017; and Prosus Ventures led a $50 million Series D in 2019 with Sequoia and Omidyar returning. Across ten rounds and 37 investors, the company raised roughly $231 million in total before Tata Digital’s entry, according to funding-tracker data reported by Inc42. Each of those backers changed something specific: Sequoia and Omidyar provided the early conviction and follow-on capital that let the company survive its 2018-19 regulatory scare; HBM’s healthcare-specialist money helped it build out diagnostics; and Prosus’s larger 2019 cheque funded the scale-up that made it an attractive acquisition target for Tata two years later.

Tata Digital’s June 2021 investment changed the calculus entirely, trading founder and early-investor control for balance-sheet security and distribution muscle. The 2022 unicorn round, reported at $1.25 billion post-money, cemented that new status. But the story has since turned again: in September 2025, Tata 1mg was reported to be in talks to raise around $200 million in fresh primary capital from Novo Holdings, the Canada Pension Plan Investment Board, Permira and ChrysCapital, according to Medical Dialogues and a separate report carried by Yahoo Finance. Those investors were pushing for a valuation of $750-800 million, a marked cut from the 2022 peak, and some had asked for board seats and additional rights that Tata was reported to have declined. If the standoff does not resolve on Tata’s terms, Tata Sons was reported to be prepared to inject roughly $75 million itself rather than accept the investors’ price or governance demands.

How it makes money

Tata 1mg earns money in three ways. The largest is straightforward medicine sales: income from selling prescription and over-the-counter drugs made up 81.3% of total revenue in FY24, according to filings reported by Entrackr and Inc42. This is a low-margin, high-volume business — the company buys or aggregates inventory, ships it to a pin code, and competes on price and reliability against physical chemists and rival apps, so procurement cost alone was ₹1,290 crore against ₹1,968 crore of revenue that year. The second stream is diagnostics: home sample collection and lab testing through owned and partner labs, running at an annualised revenue rate above ₹600 crore, a business with materially better margins because 1mg controls the testing infrastructure rather than merely reselling someone else’s product. The third and smallest stream is services revenue — teleconsultation fees, “patient support programmes” run on behalf of pharmaceutical companies for chronic-disease patients, and in-app advertising sold to drugmakers wanting shelf space on the platform.

The part outsiders tend to get wrong is which part of this actually makes money. Most people picture Tata 1mg as one business: an app that sells medicines. Its own FY26 filings, reported by Entrackr, split it into two legal entities that map roughly onto that inventory-versus-platform divide, and the results invert the popular assumption — the smaller, asset-light entity is the profitable one, and the larger, inventory-and-infrastructure-heavy entity is the one losing money (detailed in the next section). The visible, revenue-heavy side of the business is the side still burning cash; the quieter side is what is actually working.

The numbers

Two things stand out. First, the collapse in losses between FY23 and FY24 — a 75% cut in a single year, as reported by Inc42 — was the sharpest correction of the company’s disclosed financial history, achieved mainly by cutting advertising spend and controlling employee costs rather than by revenue growth alone. Second, the loss actually widened slightly in FY26, from ₹276 crore to ₹287 crore, even as revenue kept climbing 23% — a sign that the easy cost-cutting gains of FY24 have largely been captured, and that further loss reduction will now have to come from the underlying unit economics of medicine delivery and diagnostics rather than from trimming marketing budgets.

Where the money comes from

Two cuts of the business are worth looking at. By product line, medicine sales dominate at 81.3% of FY24 revenue, with diagnostics, patient-support programmes, advertising and shipping fees making up the rest — a split that has likely shifted somewhat as diagnostics scaled toward its reported ₹600-crore-plus annualised run rate, but the pharmacy business remains the clear majority. By physical footprint, the company had expanded to more than 280 retail pharmacy outlets by 2026, with plans reported to take that to around 500, alongside 21 NABL-accredited labs and a CAP-accredited national reference laboratory in Delhi that anchors home diagnostics across more than 70 cities.

The genuine surprise sits in the FY26 entity-level split reported by Entrackr. Tata 1mg Healthcare Solutions — the entity that appears to house the inventory-led pharmacy business, physical stores and diagnostics infrastructure — brought in ₹2,440 crore of revenue but posted a loss of ₹310 crore. Tata 1mg Technologies — the lighter, platform-and-marketplace entity — earned a much smaller ₹496 crore but was profitable, posting a net profit of ₹23 crore. In other words, the bulk of the company’s revenue and nearly all of its physical infrastructure sit inside the loss-making entity, while the comparatively small technology layer is where the company has actually crossed into profitability. That is close to the opposite of what most readers would assume about an “online pharmacy.”

The risks

The first risk is regulatory fragility. India still has no dedicated e-pharmacy statute; the entire industry operates under interpretations of decades-old pharmacy law, and a single public-interest petition was enough to trigger a nationwide court-ordered ban on online medicine sales once already. A stricter draft e-pharmacy rule, a fresh petition, or a court ruling on data privacy in prescription handling could force the same kind of compliance scramble again, this time on a much larger, harder-to-pivot business.

The second is competition from rivals with deeper, integrated pockets. Reliance Retail bought a majority stake in Netmeds for about $83 million in 2023 and has since folded it into JioMart’s logistics and physical Reliance Smart Point network for hyperlocal delivery, while PharmEasy, after a 2025 restructuring, has come back leaner with an aggressive subscription-discount model aimed at price-sensitive users. Tata 1mg is no longer fighting scrappy startups; it is fighting two conglomerate-backed rivals in a category where discounting and same-day logistics, not app design, decide market share.

The third is capital-allocation risk inside its own parent. Tata Digital’s own consolidated net loss was reported at ₹828 crore in FY25 across its portfolio of Croma, BigBasket, Tata 1mg and other units, even after a 31% year-on-year improvement. Tata 1mg is one of several loss-making bets competing for the same group capital, and the 2025 fundraise standoff — external investors unwilling to pay the 2022 valuation, and Tata reportedly weighing a $75 million top-up of its own rather than meet investor terms — shows that continued funding is not guaranteed to arrive on the company’s preferred timeline or price.

The takeaway

Tata 1mg’s arc argues against a simple “scale solves everything” reading of Indian startup history. Its revenue has grown every year since the Tata deal, yet its most recent external valuation conversation was about a markdown, not a markup, and its most profitable unit is also its smallest one. The transferable lesson is less about growth and more about legibility: a business that can show a strategic acquirer, and later outside investors, exactly which part of its revenue is real profit and which part is subsidised scale, is in a stronger position than one that only shows a single blended number. 1mg survived its regulatory near-miss and its worst loss year not by hiding the losses inside a bigger top line, but by eventually letting its owners see, entity by entity, where the money was actually being made and where it was being spent to buy market share.

Frequently asked questions

Who owns Tata 1mg?

Tata Digital, part of the Tata Group, is the majority owner. It acquired roughly 55% of the company in June 2021 and has since increased its holding to a reported 63-67%, with the range reflecting different figures cited by Entrackr and other reports; founder Prashant Tandon continues to run the company as CEO.

Is Tata 1mg profitable?

Not on a consolidated basis. The combined entity posted a net loss of ₹287 crore in FY26 on revenue of ₹2,936 crore. However, its Tata 1mg Technologies entity, the smaller platform arm, reported a net profit of ₹23 crore that year, according to filings reported by Entrackr, while the larger Healthcare Solutions entity carried a ₹310 crore loss.

How is Tata 1mg different from 1mg before the Tata deal?

Before June 2021, 1mg was an independently venture-funded company valued at roughly $242 million, having raised about $231 million across ten rounds. Since Tata Digital’s investment, it has scaled its retail pharmacy footprint, expanded its diagnostics lab network, and grown revenue more than four times over, from around ₹627 crore reported for FY22 to ₹2,936 crore in FY26, while operating under Tata’s brand and balance sheet.

Who are Tata 1mg’s biggest competitors?

Its main rivals are PharmEasy, which has gone through a major 2025 restructuring and now competes heavily on subscription discounts, and Reliance-owned Netmeds, integrated into JioMart’s retail and delivery network since Reliance Retail’s 2023 majority-stake acquisition. Apollo Pharmacy and Flipkart Health Plus are also active in the category. Tata 1mg was reported by Business Standard in November 2023 to hold around 31% of e-pharmacy GMV, ahead of PharmEasy’s roughly 15% at the time, making the two Tata- and Reliance-backed platforms the market’s largest.

Is Tata 1mg planning an IPO?

There is no confirmed IPO timeline as of this writing. The company’s most recent capital-raising activity, reported in September 2025, was a private fundraise of about $200 million from investors including Novo Holdings, CPPIB, Permira and ChrysCapital, centred on a valuation disagreement rather than any public-listing plan.

Sources

Figures are as of September 2026. Currency converted at $1 ≈ ₹96.0 as of 18 September 2026 (Trading Economics).

• Entrackr, “Tata 1mg revenue nears Rs 2,400 Cr in FY25, trims losses”, July 2025
• Entrackr, “Tata 1mg revenue nears Rs 3,000 Cr in FY26; loss narrows to Rs 287 Cr”, July 2026
• Entrackr, “Tata 1mg’s revenue nears Rs 2,000 Cr in FY24; losses down by 75%”, July 2024
• Inc42, “Tata 1mg FY24: Loss Declines 75% To INR 313 Cr”, July 2024
• Inc42, “Tata Digital’s FY25 Turnover Down 14%, 1mg Revenue Zooms 20%”, July 2025
• Inc42, “1MG Funding — Total Funding, Rounds & Investors” company funding database, accessed September 2026
• TechCrunch, “Tata Digital to acquire majority stake in online pharmacy 1mg”, June 2021
• Wikipedia, “Tata 1mg”, accessed September 2026
• Medical Dialogues, “Tata 1mg in Advanced Talks to Raise USD 200 Million, Valuation Standoff Emerges”, September 2025
• Yahoo Finance, “Novo, Permira and others interested in Tata 1mg despite valuation standoff”, September 2025
• StartupTalky, “Tata 1mg: Online Drug Delivery Platform | Funding | Business Model | Revenue”, accessed September 2026
• Business Standard, “Tata 1mg overtakes PharmEasy as leaders in India’s e-pharmacy market”, November 2023
• YourStory, “Tata Digital trims losses by 31% in FY25; Croma, 1MG biggest contributors to top-line”, July 2025

Found an error? Write to us and we’ll correct it in the open, dated, on the piece.